دورية أكاديمية
أعرض في EDS

Co-existence of beta-lactamases in clinical isolates of Escherichia coli from Kathmandu, Nepal.

التفاصيل البيبلوغرافية
العنوان: Co-existence of beta-lactamases in clinical isolates of Escherichia coli from Kathmandu, Nepal.
المؤلفون: Pokhrel RH, Thapa B; Department of Microbiology, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal. badri_bishal@yahoo.com., Kafle R, Shah PK, Tribuddharat C
المصدر: BMC research notes [BMC Res Notes] 2014 Oct 07; Vol. 7, pp. 694. Date of Electronic Publication: 2014 Oct 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-0500 (Electronic) Linking ISSN: 17560500 NLM ISO Abbreviation: BMC Res Notes Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Biomed Central, 2008.
مواضيع طبية MeSH: Escherichia coli/*enzymology , Escherichia coli Infections/*microbiology , Escherichia coli Proteins/*isolation & purification , beta-Lactamases/*isolation & purification, Anti-Bacterial Agents/therapeutic use ; Bacterial Proteins/isolation & purification ; Cross-Sectional Studies ; DNA, Bacterial/isolation & purification ; Drug Resistance, Bacterial ; Escherichia coli/drug effects ; Escherichia coli/genetics ; Escherichia coli/isolation & purification ; Escherichia coli Infections/diagnosis ; Escherichia coli Infections/drug therapy ; Escherichia coli Infections/epidemiology ; Escherichia coli Proteins/genetics ; Genotype ; Hospitals, Teaching ; Humans ; Microbial Sensitivity Tests ; Nepal/epidemiology ; beta-Lactamases/genetics
مستخلص: Background: The trend of extended-spectrum beta-lactamases producing Escherichia coli (ESBL-EC) is increasing in Nepal. Limited studies have been reported investigating ESBL types and carbapenemases in E. coli.
Methods: A cross sectional study was conducted between June 2012 to January 2013 in Kathmandu Medical College and Teaching Hospital, Nepal. Non-repetitive clinical samples from out-patient department (OPD) and Intensive Care Units (ICU) were processed for bacteriological culture and identification of E. coli. Antibiotic susceptibility test, screening and phenotypic confirmation for ESBLs and carbapenemases and PCR (blaCTX-M, blaSHV and blaTEM-type ESBLs, blaVIM, blaIMP and blaNDM-1-type carbapenemases, and class 1 integron element integrase gene) were performed. Clones were resolved by PCR-Randomly Amplified Polymorphic DNA.
Results: Out of 332 non-repetitive clinical specimens processed for culture and identification 160 (48.2%) were culture positive. Of which, 93 (58.1%) were E. coli. Of these, 24 (25.8%) were phenotypically confirmed as ESBL-EC and 3 (12.50%) of 24 ESBL-EC were carbapenemase producers. blaCTX-M-type ESBL was most common (23, 95.8%) followed by blaTEM (7, 29.2%) and blaSHV (3, 12.5%). blaVIM, blaIMP and blaNDM-1 were present in 3, 2 and 2 ESBL-EC, respectively. Class 1 integron element was present in 18 (75.0%) ESBL-EC. Nine isolates possessed more than one type of beta-lactamases. Interestingly, all carbapenemase producers were isolated form ICU and co-existence of blaCTX-M, blaSHV, blaTEM, blaIMP, blaVIM and blaNDM-1 beta-lactamases was documented in one ESBL-EC (EC104). All most all isolates had different RAPD patterns.
Conclusions: For the first time in Nepal, high prevalence of blaCTX-M-type ESBL and co-existence of ESBLs and carbapenemases has been described. Continuous monitoring and surveillance and proper infection control and prevention practices will limit the further spread of these super-bugs within this hospital and beyond.
References: Antimicrob Agents Chemother. 2004 Apr;48(4):1249-55. (PMID: 15047527)
Southeast Asian J Trop Med Public Health. 2010 May;41(3):625-35. (PMID: 20578551)
J Clin Microbiol. 2010 Jan;48(1):120-3. (PMID: 19889896)
Int J Antimicrob Agents. 2007 Nov;30(5):471-2. (PMID: 17851048)
Antimicrob Agents Chemother. 2009 Feb;53(2):465-75. (PMID: 19015360)
Lancet Infect Dis. 2008 Mar;8(3):159-66. (PMID: 18291338)
Ann Intensive Care. 2011 Nov 23;1:47. (PMID: 22112929)
Clin Microbiol Rev. 2008 Jan;21(1):26-59. (PMID: 18202436)
Int J Health Sci (Qassim). 2012 Jan;6(1):79-84. (PMID: 23267307)
J Glob Infect Dis. 2010 Sep;2(3):263-74. (PMID: 20927289)
Int J Antimicrob Agents. 2013 Oct;42(4):372-4. (PMID: 23978353)
BMC Res Notes. 2013 Nov 25;6:487. (PMID: 24274894)
J Med Microbiol. 2010 Jun;59(Pt 6):665-671. (PMID: 20150317)
Crit Care Res Pract. 2012;2012:625170. (PMID: 21766013)
Curr Opin Microbiol. 2006 Oct;9(5):466-75. (PMID: 16942899)
J Clin Microbiol. 2000 Jul;38(7):2766-7. (PMID: 10878083)
BMC Infect Dis. 2008 May 17;8:67. (PMID: 18485230)
Antimicrob Agents Chemother. 2011 Jul;55(7):3140-9. (PMID: 21518841)
Drugs. 2010 Feb 12;70(3):313-33. (PMID: 20166768)
GMS Krankenhhyg Interdiszip. 2011;6(1):Doc18. (PMID: 22242099)
Pak J Biol Sci. 2011 Jan 1;14(1):41-6. (PMID: 21913496)
Southeast Asian J Trop Med Public Health. 2008 May;39(3):425-33. (PMID: 18564681)
J Clin Microbiol. 2011 Feb;49(2):718-21. (PMID: 21123531)
Antimicrob Agents Chemother. 2009 Aug;53(8):3280-4. (PMID: 19506060)
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Bacterial Proteins)
0 (DNA, Bacterial)
0 (Escherichia coli Proteins)
EC 3.5.2.6 (beta-Lactamases)
EC 3.5.2.6 (carbapenemase)
تواريخ الأحداث: Date Created: 20141008 Date Completed: 20150610 Latest Revision: 20211021
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4197279
DOI: 10.1186/1756-0500-7-694
PMID: 25287013
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا